Issuer directory · Pharmaceuticals
Pharmaceuticals: private offerings on SEC Form D.
184 issuers in this group filed a Form D since 2024, reported at least $1 million sold, and either raised from ten or more investors or amended the notice at least once. Ranked by the amount reported sold on the newest notice, 100 to a page. The platform column names the AltStreet-reviewed platform an issuer belongs to; "direct" means none is on record.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Par Health, Inc. | $763.0M | 234 | 506(c) | Nov 25, 2025 | 1 | direct |
| BICYCLE THERAPEUTICS PLC | $555.5M | 19 | 506(b) | Jun 12, 2024 | 1 | direct |
| Immunovant, Inc. | $450.0M | 11 | 506(b) | Jan 21, 2025 | 1 | direct |
| TrialSpark, Inc. | $372.2M | 16 | 506(b) | Jul 2, 2024 | 1 | direct |
| DBV Technologies S.A. | $306.9M | 14 | 506(b) | Apr 17, 2025 | 1 | direct |
| Paragon Biosciences Emalex Capital, Inc. | $270.0M | 42 | 506(b) | Jul 8, 2025 | 4 | direct |
| Olema Pharmaceuticals, Inc. | $250.0M | 26 | 506(b) | Dec 12, 2024 | 1 | direct |
| MAPS Public Benefit Corp | $215.1M | 62 | 506(b) | Sep 29, 2023 | 1 | direct |
| Endo, Inc. | $170.6M | 404 | 506(b) | May 6, 2024 | 2 | direct |
| TORL Biotherapeutics LLC | $158.3M | 52 | 506(b) | Apr 17, 2024 | 1 | direct |
| Triana Biomedicines, Inc. | $120.1M | 20 | 506(b) | Dec 4, 2025 | 1 | direct |
| Pelage Pharmaceuticals, Inc. | $120.0M | 5 | 506(b) | Nov 24, 2025 | 1 | direct |
| Reunion Neuroscience, Inc. | $119.8M | 9 | 506(b) | Sep 9, 2025 | 4 | direct |
| Renibus Therapeutics, Inc. | $110.9M | 59 | 506(b) | Jul 17, 2025 | 3 | direct |
| LB PHARMACEUTICALS INC | $110.7M | 6 | 506(b) | Jan 10, 2024 | 2 | direct |
| KORTUC USA INC. | $108.7M | 14 | 506(b) | May 16, 2023 | 1 | direct |
| Quoin Pharmaceuticals, Ltd. | $105.3M | 27 | 506(b) | Oct 23, 2025 | 1 | direct |
| Context Therapeutics Inc. | $100.0M | 26 | 506(b) | May 16, 2024 | 1 | direct |
| TENAX THERAPEUTICS, INC. | $99.7M | 24 | 506(b) | Aug 23, 2024 | 1 | direct |
| Enliven Therapeutics, Inc. | $90.0M | 20 | 506(b) | Apr 3, 2024 | 1 | direct |
| BlossomHill Therapeutics, Inc. | $88.6M | 44 | 506(b) | Jan 2, 2024 | 1 | direct |
| Enlaza Therapeutics, Inc. | $84.0M | 16 | 506(b) | Aug 9, 2024 | 1 | direct |
| ALIMERA SCIENCES INC | $81.0M | 16 | 506(b) | May 31, 2023 | 2 | direct |
| Tango Therapeutics, Inc. | $80.0M | 17 | 506(b) | Aug 24, 2023 | 1 | direct |
| Aclaris Therapeutics, Inc. | $80.0M | 19 | 506(b) | Dec 4, 2024 | 1 | direct |
| LEAP THERAPEUTICS, INC. | $77.2M | 121 | 506(b) | Mar 13, 2023 | 1 | direct |
| Avilar Therapeutics, Inc. | $75.3M | 5 | 506(b) | Feb 13, 2023 | 2 | direct |
| Mind Medicine (MindMed) Inc. | $75.0M | 2 | 506(b) | Mar 18, 2024 | 1 | direct |
| Altesa BioSciences, Inc. | $75.0M | 17 | 506(b) | Feb 23, 2026 | 1 | direct |
| Ratio Therapeutics, Inc. | $70.0M | 57 | 506(b) | Jul 31, 2026 | 1 | direct |
| Rivus Pharmaceuticals, Inc. | $66.0M | 7 | 506(b) | Sep 17, 2024 | 1 | direct |
| OnKure Therapeutics, Inc. | $65.0M | 20 | 506(b) | Oct 21, 2024 | 1 | direct |
| Sparrow Pharmaceuticals, Inc. | $61.8M | 17 | 506(b) | Jul 1, 2025 | 1 | direct |
| BiomX Inc. | $61.5M | 34 | 506(b) | Apr 1, 2024 | 1 | direct |
| Arthrosi Therapeutics, Inc. | $60.9M | 13 | 506(b) | Jun 24, 2025 | 1 | direct |
| Gilgamesh Pharma Inc. | $60.0M | 40 | 506(b) | Mar 24, 2026 | 1 | direct |
| QurAlis Corp | $60.0M | 27 | 506(b) | Mar 13, 2023 | 1 | direct |
| Corner Therapeutics, Inc. | $58.5M | 14 | 506(b) | Aug 11, 2025 | 3 | direct |
| Arizona Isotopes Science Research Corp. | $58.3M | 105 | 506(b) | May 29, 2024 | 5 | direct |
| Alveus Therapeutics, Inc. | $56.9M | 17 | 506(b) | Jan 14, 2026 | 1 | direct |
| LEXICON PHARMACEUTICALS, INC. | $55.7M | 1 | 506(b) | Feb 17, 2026 | 1 | direct |
| Aeovian Pharmaceuticals, Inc. | $55.0M | 13 | 506(b) | Dec 22, 2025 | 1 | direct |
| Lomond Therapeutics Holdings, Inc. | $53.9M | 28 | 506(b) | Feb 11, 2025 | 2 | direct |
| OnKure, Inc. | $53.8M | 15 | 506(b) | Apr 3, 2023 | 1 | direct |
| vTv Therapeutics Inc. | $51.0M | 4 | 506(b) | Mar 7, 2024 | 1 | direct |
| Pelthos Therapeutics Inc. | $50.1M | 13 | 506(b) | Jul 10, 2025 | 1 | direct |
| Verrica Pharmaceuticals Inc. | $50.0M | 21 | 506(b) | Dec 10, 2025 | 1 | direct |
| HYPERION DEFI, INC. | $50.0M | 5 | 506(b) | Jul 22, 2025 | 1 | direct |
| Osteal Therapeutics, Inc. | $50.0M | 16 | 506(b) | Jun 6, 2024 | 1 | direct |
| Ikena Oncology, Inc. | $42.6M | 48 | 506(b) | Aug 18, 2023 | 1 | direct |
| Curevo, Inc. | $42.4M | 11 | 506(b) | Mar 18, 2025 | 1 | direct |
| Melt Pharmaceuticals, Inc. | $42.3M | 309 | 506(b) | Apr 8, 2024 | 9 | direct |
| Jaguar Health, Inc. | $40.8M | 1 | 506(b) | Jul 1, 2026 | 1 | direct |
| AN2 Therapeutics, Inc. | $40.0M | 16 | 506(b) | Mar 25, 2026 | 1 | direct |
| Revalesio Corp | $38.9M | 31 | 506(b) | Dec 16, 2025 | 3 | direct |
| Comanche Biopharma Corp. | $37.5M | 7 | 506(b) | Jan 17, 2024 | 1 | direct |
| Triton Therapeutics, Inc. | $36.4M | 4 | 506(b) | Oct 23, 2025 | 1 | direct |
| AlphaTON Capital Corp | $36.1M | 15 | 506(b) | Sep 17, 2025 | 1 | direct |
| Venatorx Pharmaceuticals, Inc. | $35.0M | 3 | 506(b) | Jul 13, 2023 | 2 | direct |
| Apnimed, Inc. | $35.0M | 7 | 506(b) | Dec 8, 2025 | 3 | direct |
| Cosmos Health Inc. | $32.5M | 0 | 506(b) | Jan 5, 2023 | 2 | direct |
| Ionetix Corp / DE / | $32.3M | 267 | 506(b) | Apr 23, 2026 | 1 | direct |
| Belhaven Biopharma Inc. | $32.3M | 222 | 506(b) | Oct 15, 2025 | 1 | direct |
| VST BIO Corp | $31.9M | 1 | 506(b) | Apr 24, 2026 | 2 | direct |
| Nocion Therapeutics, Inc. | $31.1M | 13 | 506(b) | Mar 13, 2024 | 1 | direct |
| Phlow Corp. | $30.5M | 9 | 506(b) | Feb 14, 2025 | 1 | direct |
| Vesalius Longevity Labs Inc. | $30.1M | 62 | 506(b) | Nov 3, 2026 | 1 | direct |
| Petros Pharmaceuticals, Inc. | $30.0M | 15 | 506(b) | Jul 21, 2023 | 1 | direct |
| Relay Therapeutics, Inc. | $30.0M | 1 | 506(b) | Jan 10, 2024 | 1 | direct |
| NEKTAR THERAPEUTICS | $30.0M | 1 | 506(b) | Mar 19, 2024 | 1 | direct |
| Kinaset Therapeutics, Inc. | $28.5M | 3 | 506(b) | Jul 17, 2023 | 2 | direct |
| Spiral Therapeutics Inc | $27.1M | 34 | 506(b) | Apr 16, 2026 | 1 | direct |
| MyMD Pharmaceuticals, Inc. | $26.9M | 4 | 506(b) | May 31, 2024 | 1 | direct |
| Sensorium Therapeutics, Inc. | $26.8M | 19 | 506(b) | Jul 15, 2025 | 2 | direct |
| Spectrum Antimicrobials, Inc. | $26.4M | 247 | 506(c) | Apr 1, 2026 | 7 | direct |
| Avenacy Inc. | $26.0M | 2 | 506(b) | Nov 26, 2024 | 1 | direct |
| 858 Therapeutics, Inc. | $25.2M | 12 | 506(b) | Jul 11, 2024 | 1 | direct |
| CNS Pharmaceuticals, Inc. | $22.5M | 13 | 506(b) | May 19, 2026 | 1 | direct |
| AXIAL THERAPEUTICS, INC. | $19.4M | 29 | 506(b) | Feb 11, 2025 | 1 | direct |
| Capacity Bio, Inc. | $19.2M | 13 | 506(b) | Jan 18, 2023 | 1 | direct |
| Artax Biopharma, Inc. | $19.0M | 30 | 506(b) | May 5, 2026 | 3 | direct |
| CytoDyn Inc. | $18.6M | 194 | 506(b) | May 11, 2026 | 1 | direct |
| Paulex Bio Inc. | $18.5M | 163 | 506(c) | Dec 18, 2025 | 1 | direct |
| Land Therapeutics Inc. | $17.5M | 12 | 506(b) | Oct 21, 2026 | 2 | direct |
| TALPHERA, INC. | $17.0M | 13 | 506(b) | Sep 15, 2025 | 1 | direct |
| Neumentum, Inc. | $16.6M | 33 | 506(b) | Apr 28, 2023 | 3 | direct |
| EIKONOKLASTES THERAPEUTICS, INC. | $16.1M | 15 | 506(b) | Oct 6, 2026 | 2 | direct |
| Evergreen Theragnostics Inc. | $15.5M | 58 | 506(b) | Aug 18, 2023 | 1 | direct |
| MindImmune Therapeutics, Inc. | $15.2M | 15 | 506(b) | Mar 5, 2026 | 2 | direct |
| RENOVION, INC. | $15.0M | 24 | 506(b) | Mar 28, 2023 | 1 | direct |
| KIORA PHARMACEUTICALS INC | $15.0M | 13 | 506(b) | Feb 14, 2024 | 1 | direct |
| Incyclix Bio, LLC | $15.0M | 5 | 506(b) | Jul 6, 2023 | 2 | direct |
| Kamal Therapeutics, Inc. | $13.8M | 41 | 506(b) | Nov 24, 2025 | 1 | direct |
| Spine BioPharma, Inc. | $13.5M | 10 | 506(b) | Dec 18, 2024 | 1 | direct |
| Acta Pharmaceuticals, Inc. | $13.4M | 29 | 506(b) | Apr 22, 2024 | 2 | direct |
| Groff North America, LLC | $13.1M | 24 | 506(b) | Jul 14, 2023 | 1 | direct |
| ZETAGEN THERAPEUTICS, INC. | $12.9M | 35 | 506(b) | Nov 12, 2025 | 2 | direct |
| Enveric Biosciences, Inc. | $12.8M | 2 | 506(b) | Apr 19, 2023 | 2 | direct |
| resistanceBio, Inc. | $12.8M | 44 | 506(b) | Jan 31, 2024 | 1 | direct |
| Sentonix, Inc. | $12.7M | 17 | 506(b) | Aug 20, 2026 | 1 | direct |
Source: SEC EDGAR Form D and D/A filings. A Form D is a notice of an exempt offering; the SEC does not review or approve the offering. Reported figures are the issuer's own. Other groups: the full directory.
